Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Ge...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced that th...
Ouroboros Family Founders Fund I, LP announced this week it will lead a $60 million Series A financing in Cytotheryx, Inc., a preclinical cell therapy comp...
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss ...
Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-ter...
ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...
Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnin...
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's ...
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myelo...
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 i...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications ...
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...
© 2026 Biopharma Boardroom. All Rights Reserved.
